Rapport Therapeutics, Inc. (RAPP)
26.07
+1.63
(+6.67%)
USD |
NASDAQ |
Nov 09, 16:00
26.03
-0.04
(-0.15%)
After-Hours: 20:00
Rapport Therapeutics Enterprise Value : 867.92M for Nov. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 09, 2026 | 867.92M |
| November 06, 2026 | 789.54M |
| November 05, 2026 | 754.91M |
| November 04, 2026 | 861.19M |
| November 03, 2026 | 837.63M |
| November 02, 2026 | 822.72M |
| October 30, 2026 | 818.87M |
| October 29, 2026 | 778.48M |
| October 28, 2026 | 696.25M |
| October 27, 2026 | 938.61M |
| October 26, 2026 | 832.34M |
| October 23, 2026 | 861.19M |
| October 22, 2026 | 890.04M |
| October 21, 2026 | 819.35M |
| October 20, 2026 | 1.027B |
| October 19, 2026 | 989.59M |
| October 16, 2026 | 940.05M |
| October 15, 2026 | 1.036B |
| October 14, 2026 | 976.60M |
| October 13, 2026 | 1.008B |
| October 12, 2026 | 1.064B |
| October 09, 2026 | 1.088B |
| October 08, 2026 | 1.050B |
| October 07, 2026 | 1.098B |
| October 06, 2026 | 1.112B |
| Date | Value |
|---|---|
| October 05, 2026 | 1.162B |
| October 02, 2026 | 1.161B |
| October 01, 2026 | 1.193B |
| September 30, 2026 | 1.230B |
| September 29, 2026 | 1.157B |
| September 28, 2026 | 1.178B |
| September 25, 2026 | 1.200B |
| September 24, 2026 | 1.196B |
| September 23, 2026 | 1.211B |
| September 22, 2026 | 1.563B |
| September 21, 2026 | 1.476B |
| September 18, 2026 | 1.514B |
| September 17, 2026 | 1.586B |
| September 16, 2026 | 1.559B |
| September 15, 2026 | 1.621B |
| September 14, 2026 | 1.684B |
| September 11, 2026 | 1.666B |
| September 10, 2026 | 1.658B |
| September 09, 2026 | 1.678B |
| September 08, 2026 | 1.784B |
| September 04, 2026 | 1.769B |
| September 03, 2026 | 1.859B |
| September 02, 2026 | 1.909B |
| September 01, 2026 | 1.903B |
| August 31, 2026 | 1.908B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 706.50B |
| ANI Pharmaceuticals, Inc. | 1.723B |
| Corcept Therapeutics, Inc. | 7.843B |
| Veru, Inc. | 14.23M |
| Eli Lilly & Co. | 1.374T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.24M |
| Total Expenses (Quarterly) | 40.24M |
| EPS Diluted (Quarterly) | -0.8423 |
| Earnings Yield | -12.17% |
| Normalized Earnings Yield | -12.17 |